{
  "url": "https://www.law.cornell.edu/regulations/new-york/9-NYCRR-113.1",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 9 § 113.1 - Definitions",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 9 § 113.1 - Definitions\n\nState Regulations\n\nFor the purposes of this Part, the following terms shall\nhave the following meanings: (a) Adverse event\nmeans any untoward medical occurrence associated\nwith the use of a medical cannabis product in humans. (b) Advertising\nmeans\nadvertising as defined in Part 128 of this Title. (c) Advertisement means advertisement defined\nin Part 128 of this Title. (d) Aggregate ownership means aggregate ownership as defined in Part 118 of this\n\nTitle. (e) Artificially\nderived phytocannabinoid\nmeans artificially derived phytocannabinoid\nas defined in Part 118 of this Title. (f) Board\nmeans the New York\n\nState Cannabis Control Board as defined in article 1 of the Cannabis\n\nLaw. (g) Brand or\n\nBranding\nmeans the name, entity name, or doing business as name, registered trademark, logo, symbol, motto, selling message, recognizable\npattern of colors, or any other identifiable marker that identifies one (1)\nmedical cannabis registrant or medical cannabis registrant's medical cannabis\nproducts as distinct from those cannabis products of other medical cannabis\nregistrants or adult-use cannabis licensees and is used in, among other things, any packaging, labeling, advertising or marketing. (h) Caring for\nmeans\ntreating a patient, in the course of which the practitioner has completed a\nfull assessment of the patient's medical history and current medical\ncondition. (i) Certificate\nof analysis\nmeans a certified report from a cannabis laboratory\nmeeting the testing requirements of section\n113.15\nof this Part. (j) Certified medical use\nmeans the acquisition, cultivation, manufacture, delivery, harvest, possession, preparation, transfer, transportation, or use of medical cannabis for a\ncertified patient, or the acquisition, administration, cultivation, manufacture, delivery, harvest, possession, preparation, transfer, or\ntransportation of medical cannabis by a designated caregiver or designated\ncaregiver facility, or paraphernalia relating to the administration of\ncannabis, including whole cannabis flower, to treat or alleviate a certified\npatient's medical condition or symptoms associated with the patient's medical\ncondition. (k) Certified\npatient\nmeans a patient who is a resident of New York or receiving\ncare and treatment in New York State and is certified in accordance with\nsection\n113.3\nof this Part. (l) Child-Resistant\nmeans\nchild-resistant as defined in Part 128 of this Title. (m) Condition\nmeans having\n(1) one of the following conditions: cancer, positive status for human\nimmunodeficiency virus or acquired immune deficiency syndrome, amyotrophic\nlateral sclerosis, Parkinson's disease, multiple sclerosis, damage to the\nnervous tissue of the spinal cord with objective neurological indication of\nintractable spasticity, epilepsy, inflammatory bowel disease, neuropathies, Huntington's disease, post-traumatic stress disorder, pain that degrades health\nand functional capability (where the use of medical cannabis is an alternative\nto opioid use), substance use disorder, Alzheimer's, muscular dystrophy, dystonia, rheumatoid arthritis, autism or any other condition certified by the\npractitioner. (n) Control\nor controlling interest means control or controlling\ninterest as defined in Part 118 of this Title. (o) Date of expiration or expiration\ndate\nmeans the date prior to which an unopened medical cannabis\nproduct meets applicable standards of identity, potency, and quality at the\ntime of use, as determined by appropriate data, subject to any storage\nconditions stated on the labeling. (p) Designated caregiver\napplicant\nmeans a natural person who is applying to obtain, amend or\nrenew a registry identification number. (q) Designated caregiver\nfacility\nmeans a facility that registers with the office to assist one\n(1) or more certified patients with the acquisition, possession, delivery, transportation or administration of medical cannabis and is a: general hospital\nor residential health care facility operating pursuant to article 28 of the\n\nPublic Health Law; an adult care facility operating pursuant to title 2 of\narticle 7 of the Social Services Law; a community mental health residence\nestablished pursuant to section\n41.44\nof\nthe Mental Hygiene Law; a hospital operating pursuant to section\n7.17\nof the\n\nMental Hygiene Law; a mental hygiene facility operating pursuant to article 31\nof the Mental Hygiene Law; an inpatient or residential treatment program\ncertified pursuant to article 32 of the Mental Hygiene Law; a residential\nfacility for the care and treatment of persons with developmental disabilities\noperating pursuant to article 16 of the Mental Hygiene Law; a residential\ntreatment facility for children and youth operating pursuant to article 31 of\nthe Mental Hygiene Law; a private or public school; research institution with\nan internal review board; or any other facility as determined by the\noffice. (r) Exit\npackage\nmeans a receptacle into which medical cannabis products are\nplaced at the point of sale. The exit package is optional. (s) Financial Interest\nmeans\nfinancial interest as defined in Part 118 of this Title. (t) Form of medical cannabis\nor\nform\nmeans form of medical cannabis as defined by article 1\nof the Cannabis Law. (u) Goods and services\nagreement means good and services agreement\nas decscirbed in Part 124 of this Title. (v) House of worship\nmeans\nhouse of worship as defined in Part 118 of this Title. (w) Lot\nmeans a quantity of\na medical cannabis product that has a homogenous and uniform phytocannabinoid\nconcentration and product quality, produced according to a stable processing\nprotocol specific to that product, during the same cycle of\nmanufacture. (x) Lot unique\nidentifier or lot number or bar code\nmeans lot unique identifier or\nlot number or bar code as defined in Part 118 of this Title. (y) Marketing means marketing as defined in\n\nPart 128 of this Title. (z) Manufacturing\nshall include, but not be limited to\ncultivation, harvesting, extraction (or other processing), packaging and\nlabeling. (aa)\n\nMedical\ncannabis product\nis the final manufactured product of medical\ncannabis, as defined in section 3 of article 1 of the Cannabis Law, delivered\nto the patient that represents a specific phytocannabinoid concentration and\nform and active and inactive ingredients, prepared in a specific dosage and\nform, to be administered as recommended by the practitioner. (ab)\n\nOffice\nmeans the New\n\nYork State Office of Cannabis Management as defined in article 1 of the\n\nCannabis Law. (ac)\n\nPassive\n\nInvestor\nmeans passive investor as defined in Part 118 of this\n\nTitle. (ad)\n\nPerson\nresponsible for making health care decisions\nmeans, in association\nwith certified patients under the age of eighteen (18) or otherwise incapable\nof consent, a person legally authorized to make health care decisions for the\npatient, including decisions on the use of medical cannabis and the designation\nof caregivers. (ae)\n\nPhytocannabinoid\nmeans phytocannabinoid as defined in Part 128\nof this Title. (af)\n\nPlastic\nmeans plastic as defined in Part 128 of this\n\nTitle. (ag)\n\nPost-consumer\nrecycled content\nmeans post-consumer recycled content as defined in\n\nPart 128 of this Title. (ah)\n\nPractitioner\nmeans an individual who is licensed, registered\nor certified by New York State to prescribe controlled substances within the\nstate. Nothing in this Part shall be interpreted so as to give any such person\nauthority to act outside their scope of practice as defined by title 8 of the\n\nEducation Law. Additionally, nothing in this Part shall be interpreted to allow\nany unlicensed, unregistered, or uncertified person to act in a manner that\nwould require a license, registration, or certification pursuant to title 8 of\nthe Education Law. (ai)\n\nPrincipal packaging display panel\nmeans the panel of the\npackage or the marketing layer that the registered organization intends to be\ndisplayed at the dispensing site. (aj)\n\nRegistered organization\nmeans an organization registered as defined under article 1 of the Cannabis\n\nLaw. (ak)\n\nRegistered\norganization applicant\nmeans an organization that has a significant\npresence in New York State and is applying to be registered or to renew a\nregistration as a registered organization. (al)\n\nRegistry application\nmeans an application properly completed and filed with the Office by a\ncertified patient in accordance with article 3 of the Cannabis Law and this\n\nPart. (am)\n\nRegistry\nidentification card\nmeans a document that identifies a certified\npatient or designated caregiver, as provided under article 3 of the Cannabis\n\nLaw. (an)\n\nResealable\nmeans resealable as defined in Part 128 of this\n\nTitle. (ao)\n\nSchool\ngrounds\nmeans school grounds as defined in Part 118 of this\n\nTitle. (ap)\n\nSerious adverse\nevent\nmeans one (1) or more of the following outcomes: death, a\nlifethreatening adverse event, inpatient hospitalization or prolongation of\nexisting hospitalization, a persistent or significant incapacity or substantial\ndisruption of the ability to conduct normal life functions, or a congenital\nanomaly/birth defect. (aq)\n\nSignificant presence\nmeans significant presence as defined in\n\nCannabis Law section 3(1). (ar)\n\nSole Control\nmeans sole control as defined in Part 118 of this\n\nTitle. (as)\n\nSpecial branding\nmaterial means a visual or audio element which shall only be for use in, packaging, labeling, marketing and advertising by certain registered\norganizations or on certain medical cannabis products including, but not\nlimited to, a designation that a licensee is a social and economic equity\nlicensee. All special branding materials and brands or products authorized to\nuse such material shall be defined, made available, and designated for use in\nguidance. (at)\n\nSynthetic\ncannabis additives\nmeans any chemical substances that do not naturally\noccur in cannabis sativa. (au)\n\nSynthetic terpenes\nmeans any terpenes that do not naturally\noccur in cannabis sativa or that are produced and created by chemical synthesis\nor biosynthesis that changes the molecular structure of a chemical substance to\ncreate a terpene that is naturally occurring in cannabis sativa. (av)\n\nTamper-evident\nmeans\ntamper-evident as defined in Part 128 of this Title. (aw)\n\nTrue Party of Interest\nmeans true party of interest as defined in Part 118 of this Title. (ax)\n\nUse by date\nmeans the\ndate prior to which an opened medical cannabis product meets applicable\nstandards of identity, potency, and quality at the time of use, as determined\nby appropriate data, subject to any storage conditions stated on the\nlabel. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 9\n§\n113.1\n\nAdopted\n\nNew\n\nYork State Register February 22, 2023/Volume XLV, Issue 08, eff. 2/22/2023\n\nAmended\n\nNew\n\nYork State Register March 27, 2024/Volume XLVI, Issue 13, eff. 3/27/2024\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. For the purposes of this Part, the following terms shall have the following meanings: (a) Adverse event\nmeans any untoward medical occurrence associated with the use of a\nmedical cannabis product\nin humans. (b) Advertising\nmeans disseminating communications in any manner or by any means, for the purpose of causing, directly or indirectly, the purchase or use of a\nmedical cannabis product\nbrand or\nmedical cannabis product, including but not limited to websites, social media, brochures, prints ads, TV, radio, streaming, out of home, and digital advertisements. (c) Artificially derived phytocannabinoid\nmeans a\nphytocannabinoid\nthat is created by a chemical reaction that changes the molecular\nstructure\nof any chemical substance derived from cannabis sativa. Artificially derived phytocannabinoid\ndoes not include: a naturally-occurring chemical substance that is separated from cannabis sativa by a chemical or\nmechanical extraction\nprocess; phytocannabinoids\nthat are produced by decarboxylation of the\nphytocannabinoid\n's respective naturally-occurring carboxylic acid\nform\nwithout the use of a chemical catalyst; any other chemical substance identified by the\n\nBoard. (d) Board\nmeans Cannabis\n\nControl\n\nBoard. (e) Brand or Branding\nmeans the name, entity name, or doing business as name, registered trademark, logo, symbol, motto, selling message, recognizable pattern of colors, or any other identifiable marker that identifies one (1) medical cannabis registrant or medical cannabis registrant's medical cannabis products as distinct from those cannabis products of other medical cannabis registrants or adult-use cannabis licensees and is used in, among other things, any packaging, labeling, advertising\nor marketing. (f) Caring for\nmeans treating a patient, in the course of which the\npractitioner\nhas completed a full assessment of the patient's medical history and current medical\ncondition. (g) Certificate of analysis\nmeans a certified report from a cannabis laboratory meeting the testing requirements of section\n113.15\nof this Part. (h) Certified medical\nuse means the acquisition, cultivation, manufacture, delivery, harvest, possession, preparation, transfer, transportation, or use of medical cannabis for a\ncertified patient, or the acquisition, administration, cultivation, manufacture, delivery, harvest, possession, preparation, transfer, or transportation of medical cannabis by a designated caregiver or\ndesignated caregiver facility, or paraphernalia relating to the administration of cannabis, including whole cannabis flower, to treat or alleviate a\ncertified patient\n's medical\ncondition\nor symptoms associated with the patient's medical\ncondition. (i) Certified patient\nmeans a patient who is a resident of New York or receiving care and treatment in New York\n\nState\nand is certified in accordance with section\n113.3\nof this Part. (j) Child-Resistant\nmeans a\nresealable\npackage for dispensing any cannabis product intended for more than a single use or containing multiple doses, that is designed or constructed to be significantly difficult for children under five (5) years of age to open and not difficult for adults to use properly as defined by 16 C.F.R. §\n1700.15\nand 16 C.F.R. §\n1700.20. (k) Condition\nmeans having one of the following conditions: cancer, positive status for human immunodeficiency virus or acquired immune deficiency syndrome, amyotrophic lateral sclerosis, Parkinson's disease, multiple sclerosis, damage to the nervous tissue of the spinal cord with objective neurological indication of intractable spasticity, epilepsy, inflammatory bowel disease, neuropathies, Huntington's disease, post-traumatic stress disorder, pain that degrades health and functional capability (where the use of medical cannabis is an alternative to opioid use), substance use disorder, Alzheimer's, muscular dystrophy, dystonia, rheumatoid arthritis, autism or any other\ncondition\ncertified by the\npractitioner. (l) Control\nmeans the power, from a business organization and ownership perspective, to order or direct the management, managers, or policies of a\nperson. (m) Date of expiration\nor\nexpiration date\nmeans the date prior to which an unopened\nmedical cannabis product\nmeets applicable standards of identity, potency, and quality at the time of use, as determined by appropriate stability testing, subject to any storage conditions stated on the labeling. (n) Designated caregiver applicant\nmeans a natural\nperson\nwho is applying to obtain, amend or renew a registry identification number. (o) Designated caregiver facility\nmeans a facility that registers with the\n\nOffice\nto assist one (1) or more certified patients with the acquisition, possession, delivery, transportation or administration of medical cannabis and is a: general hospital or residential health care facility operating pursuant to Article 28 of the Public Health\n\nLaw; an adult care facility operating pursuant to Title 2 of Article 7 of the Social Services\n\nLaw; a community mental health residence established pursuant to section\n41.44\nof the Mental Hygiene\n\nLaw; a hospital operating pursuant to section\n7.17\nof the Mental Hygiene\n\nLaw; a mental hygiene facility operating pursuant to Article 31 of the Mental Hygiene\n\nLaw; an inpatient or residential treatment\nprogram\ncertified pursuant to Article 32 of the Mental Hygiene\n\nLaw; a residential facility for the care and treatment of persons with developmental disabilities operating pursuant to Article 16 of the Mental Hygiene\n\nLaw; a residential treatment facility for children and youth operating pursuant to Article 31 of the Mental Hygiene\n\nLaw; a private or public school; research institution with an internal review\nboard; or any other facility as determined by the\n\nOffice. (p) Exit package\nmeans a receptacle into which medical cannabis products are placed at the point of sale. The\nexit package\nis optional. (q) Financial Interest\nmeans any actual or future right to ownership, investment or compensation arrangement with another\nperson, either directly or indirectly, through business, investment, spouse, parent or child. Person\nwith a\nfinancial interest\ndoes not include a\npassive investor. (r) Form of medical cannabis\nor\n\nForm\nmeans \"\nform of medical cannabis\n\" as defined by Article 1 of the Cannabis\n\nLaw. (s) Lot\nmeans a quantity of a\nmedical cannabis product\nthat has a homogenous and uniform\nphytocannabinoid\nconcentration and product quality, produced according to a stable\nprocessing\nprotocol specific to that product, during the same cycle of manufacture. (t) Lot\nunique identifier (\nLot\nnumber or bar code)\nmeans any distinctive combination of letters, numbers, or symbols, or any combination of them, from which the complete history of\nmanufacturing, testing, holding, distribution or recall of a\nlot\nof\nmedical cannabis product\ncan be determined. (u) Manufacturing\nshall include, but not be limited to\ncultivation, harvesting, extraction (or other\nprocessing\n), packaging and labeling. (v) Medical cannabis license\nmeans a registration provided to a\nregistered organization. Medical cannabis license\nand registration as it pertains to a\nregistered organization\nshall be used interchangeably. (w) Medical cannabis product\nis the final manufactured product of medical cannabis, as defined in section 3 of Article 1 of the Cannabis\n\nLaw, delivered to the patient that represents a specific\nphytocannabinoid\nconcentration and\nform\nand active and inactive ingredients, prepared in a specific dosage and\nform, to be administered as recommended by the\npractitioner. (x) Office\nmeans the\n\nOffice\nof Cannabis Management. (y) Person\nresponsible for making health care decisions\nmeans, in association with certified patients under the age of eighteen (18) or otherwise incapable of consent, a\nperson\nlegally authorized to make health care decisions for the patient, including decisions on the use of medical cannabis and the\ndesignation\nof caregivers. (z) Phytocannabinoids\nrefers to any of the chemical compounds, excluding terpenes or any other compounds determined by the\n\nOffice, that are the active principles of the cannabis sativa, including but not limited to tetrahydrocannabinol (THC) and CBD, and does not include synthetic cannabinoids as that term is defined in subdivision (g) of schedule I of section\n3306\nof the Public Health\n\nLaw. (aa)\n\nPost-consumer recycled material\nmeans new material produced using material resulting from the recovery, separation, collection and reprocessing of material that would otherwise be disposed of or processed as waste and that was originally sold for consumption. It does not include post-industrial material, or material generated by means of combustion, incineration, pyrolysis, gasification, solvolysis, chemical recycling and any high-heat or conversion process. (ab)\n\nPractitioner\nmeans an\nindividual\nwho is licensed, registered or certified by New York\n\nState\nto prescribe controlled substances within the\nstate. Nothing in this Part shall be interpreted so as to give any such\nperson\nauthority\nto\nact\noutside their scope of practice as defined by Title 8 of the Education\n\nLaw. Additionally, nothing in this Part shall be interpreted to allow any unlicensed, unregistered, or uncertified\nperson\nto\nact\nin a manner that would require a\nlicense, registration, or certification pursuant to Title 8 of the Education\n\nLaw. (ac)\n\nPrincipal packaging display panel\nmeans the panel of the package or the marketing layer that the\nregistered organization\nintends to be displayed at the dispensing\nsite. (ad)\n\nRegistered organization\nmeans an organization registered as defined under section\n3\nof the Cannabis\n\nLaw. (ae)\n\nRegistered organization applicant\nmeans an organization that has a\nsignificant presence\nin New York\n\nState\nand is applying to be registered or to renew a registration as a\nregistered organization. (af)\n\nRegistry application\nmeans an application properly completed and\nfiled\nwith the\n\nOffice\nby a\ncertified patient\nin accordance with Article 3 of the Cannabis\n\nLaw\nand this Part. (ag)\n\nRegistry identification card\nmeans a document that identifies a\ncertified patient\nor designated caregiver, as provided under Article 3 of the Cannabis\n\nLaw. (ah)\n\nResealable\nmeans a package that maintains its\nchild-resistant\neffectiveness, as well as preserving the integrity of cannabis products for multiple doses. (ai)\n\nSerious adverse event\nmeans one (1) or more of the following outcomes: death, a life- threatening\nadverse event, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or a congenital anomaly/birth defect. (aj)\n\nSignificant presence\nmeans\nsignificant presence\nas defined in Cannabis\n\nLaw\nsection 3(1). (ak)\n\nSynthetic cannabis additives refer to any chemical substances that do not naturally occur in cannabis sativa. (al)\n\nSynthetic terpenes refer to any terpenes that do not naturally occur in cannabis sativa or that are produced and created by chemical synthesis or biosynthesis that changes the molecular\nstructure\nof a chemical substance to create a terpene that is naturally occurring in cannabis sativa. (am)\n\nTamper-evident\nmeans, with respect to a device or process, bearing a seal, a label or a marking that makes unauthorized access to or tampering with a package, product or container easily detectable. (an)\n\nUse by date\nmeans the date prior to which an opened\nmedical cannabis product\nmeets applicable standards of identity, potency, and quality at the time of use, as determined by appropriate stability testing, subject to any storage conditions stated on the labeling. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 9\n§\n113.1\n\nAdopted\n\nNew York\n\nState\n\nRegister February 22, 2023/Volume XLV, Issue 08, eff. 2/22/2023",
  "url_type": "regulation",
  "source_index": 54345
}